The IP Solution
Leveraging our extensive experience with the New Technology Add-On Payment (NTAP) application process, Innovation Partners successfully acquired an NTAP designation for the novel therapy.
Our success was the result of a proven process:
Using extensive analysis, we ensured that the therapy met CMS criteria for Newness, Cost Threshold, and Substantial Clinical Improvement.
We engaged in meetings with regulatory decision-makers and harnessed support from Key Opinion Leaders—including clinical experts, advocacy groups, and professional societies—in support of the NTAP. All leading to the development and submission of the application to the CMS.